--- title: "Regentis Biomaterials (RGNT) news: going concern and offering" url: "https://aibio.space/companies/regentis-biomaterials/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RGNT going concern and offering news: Regentis Biomaterials discloses going concern qualification in 2025 audit opinion. Regentis Biomaterials Ltd." --- RGNT Regentis Biomaterials Ltd. AMEX · Israel # Regentis Biomaterials (RGNT) news RGNT going concern and offering news Financings · 2026-09-11 ## [Regentis reports $9.0 million cash after $6.5 million June private placement](https://aibio.space/news/regentis-reports-9-0-million-cash-after-6-5-million-june-private/) Regentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026. ## Latest Regentis Biomaterials news 1. 2026-05-01 Financings [Regentis Biomaterials files to sell 3,333,334 shares at an assumed $3.00](https://aibio.space/news/regentis-biomaterials-files-sell-3-333-334-shares-assumed-3-00/) Regentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close. 2. 2026-02-24 Listings [Regentis Biomaterials discloses going concern qualification in 2025 audit opinion](https://aibio.space/news/regentis-biomaterials-discloses-going-concern-qualification-2025-audit/) Regentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling. ## Regentis Biomaterials at a glance - **Ticker**: RGNT - **Listing**: AMEX - **Country**: Israel - **Cash, Dec 31, 2025**: $7.4 million ### Related companies - [Pluri](https://aibio.space/companies/pluri/) NASDAQ: PLUR - [Chemomab Therapeutics](https://aibio.space/companies/chemomab-therapeutics/) NASDAQ: CMMB - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) TASE: NRGN - [Kamada](https://aibio.space/companies/kamada/) NASDAQ: KMDA - [Evogene](https://aibio.space/companies/evogene/) NASDAQ: EVGN - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Polyrizon](https://aibio.space/companies/polyrizon/) NASDAQ: PLRZ - [Matricelf](https://aibio.space/companies/matricelf/) TASE: MTLF ### Also on AMEX - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [Oragenics](https://aibio.space/companies/oragenics/) OGEN - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) CLDI - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AEON - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA ## Regentis Biomaterials annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$13.6 million](https://www.sec.gov/Archives/edgar/data/1912966/000121390026021722/) | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1912966/000121390026021722/) | | Cash from operations | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/1912966/000121390026021722/) | [-$641,000](https://www.sec.gov/Archives/edgar/data/1912966/000121390026021722/) | | Cash and equivalents | [$7.4 million](https://www.sec.gov/Archives/edgar/data/1912966/000121390026021722/) | | Latest balance sheet, Dec 31, 2025 (20-F/A): cash and equivalents $7.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Regentis Biomaterials Has Regentis Biomaterials issued a going-concern warning? Our latest story on this, dated Feb 24, 2026: "Regentis Biomaterials discloses going concern qualification in 2025 audit opinion". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regentis-biomaterials-discloses-going-concern-qualification-2025-audit/). Has Regentis Biomaterials raised money recently? Our latest story on this, dated Sep 11, 2026: "Regentis reports $9.0 million cash after $6.5 million June private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regentis-reports-9-0-million-cash-after-6-5-million-june-private/). What is the ticker symbol of Regentis Biomaterials? Regentis Biomaterials Ltd. trades under the ticker RGNT on AMEX. Where is Regentis Biomaterials listed? Regentis Biomaterials Ltd. is listed on AMEX. What is the SEC CIK of Regentis Biomaterials? The SEC Central Index Key (CIK) for Regentis Biomaterials Ltd. is 1912966. Its filings are on SEC EDGAR. How many shares does Regentis Biomaterials have outstanding? 5,179,378 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-02-24. Which country or territory is Regentis Biomaterials listed under? Our directory records Regentis Biomaterials Ltd. under Israel. What does Regentis Biomaterials do? Our directory classifies Regentis Biomaterials Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Regentis Biomaterials? The ISIN recorded for Regentis Biomaterials Ltd. is IL0012190968. Does aibio.space cover Regentis Biomaterials? aibio.space lists Regentis Biomaterials Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Regentis Biomaterials incorporated? SEC records list its state or country of incorporation as L3. Is Regentis Biomaterials profitable? Regentis Biomaterials Ltd. reported a net loss of $13.6 million for the fiscal year ended Dec 31, 2025, and used $1.4 million of cash in operations, per its annual report to the SEC. How much cash does Regentis Biomaterials have? $7.4 million in cash at Dec 31, 2025, per its 20-F/A. What is the latest Regentis Biomaterials (RGNT) stock news? Our latest story on Regentis Biomaterials, dated Sep 11, 2026: "Regentis reports $9.0 million cash after $6.5 million June private placement". Regentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026. [Source](https://aibio.space/news/regentis-reports-9-0-million-cash-after-6-5-million-june-private/). How long will Regentis Biomaterials's cash last? From our story of Feb 24, 2026: Regentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. [Source](https://aibio.space/news/regentis-biomaterials-discloses-going-concern-qualification-2025-audit/). ## Investor discussion: Regentis Biomaterials Members talk about Regentis Biomaterials (RGNT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Regentis Biomaterials, newest first. Each line links the filing it comes from. 1. 2026-09-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390026099007/ea030477101ex99-1.htm) 2. 2026-06-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390026070229/ea029523201ex99-1.htm) 3. 2026-05-01 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390026051034/ea0288117-f1_regentis.htm) 4. 2026-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390026019896/ea027805901ex99-1_regentis.htm) 5. 2026-02-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390026019917/ea0277515-20f_regentis.htm) 6. 2025-12-05 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390025118725/ea026858601ex99-1_regentis.htm) 7. 2025-03-11 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1912966/000121390025022350/ea0233222-f1_regentisbio.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:RGNT on TradingView](https://www.tradingview.com/symbols/AMEX-RGNT/). ## SEC filings and registration - **SEC name**: Regentis Biomaterials Ltd. - **CIK**: 1912966 - **Industry (SIC)**: Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) - **US tickers**: RGNT (NYSE) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 12 HA'ILAN STREET, NORTHERN INDUSTRIAL, OR AKIVA - **Phone**: 30600 - **Shares outstanding**: 5,179,378 as of 2025-12-31 (20-F filed 2026-02-24) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026108632/ea0308320-6k_regentis.htm) filed 2026-10-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026099007/ea0304771-6k_regentis.htm) filed 2026-09-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026079444/ea0298523-6k_regentis.htm) filed 2026-07-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026078150/ea0298098-6k_regentis.htm) filed 2026-07-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026076745/ea0297541-6k_regentis.htm) filed 2026-07-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026075015/ea0296933-6k_regentis.htm) filed 2026-07-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026070229/ea0295232-6k_regentis.htm) filed 2026-06-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1912966/000121390026068601/ea0294796-6k_regentis.htm) filed 2026-06-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001912966), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Regentis Biomaterials Ltd. is a public biotech or pharmaceutical company listed on AMEX under the ticker RGNT, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Regentis Biomaterials Ltd. - **Ticker**: RGNT - **Listing**: AMEX - **Country or territory**: Israel - **Business scope**: Biotechnology - **ISIN**: IL0012190968 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-RGNT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/regentis-biomaterials/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Regentis Biomaterials (RGNT) news: going concern and offering", 2026-10-31, https://aibio.space/companies/regentis-biomaterials/